Malamut Richard 4/A

4/A · Pelthos Therapeutics Inc. · Filed Apr 1, 2026

AI-generated summary of this filing

Updated Apr 1, 2026

Pelthos (PTHS) Director Richard Malamut Receives Stock Award

What Happened

Richard Malamut, a member of Pelthos Therapeutics' board of directors, received restricted stock unit (RSU) awards (transaction code A) on three dates: 6,450 RSUs on 2024-06-14, 19,108 RSUs on 2025-07-02, and 2,454 RSUs on 2025-11-13. The combined total reported in this amended filing is 28,012 RSUs (amounts adjusted for a 1-for-10 reverse split).
Each award is reported at $0.00 per share (typical for RSU grants, which are compensation rather than cash purchases). These RSUs represent the right to receive one share of Pelthos common stock upon vesting.

Key Details

Transaction dates and prices:
- 2024-06-14 — 6,450 RSUs @ $0.00 (acquired)
- 2025-07-02 — 19,108 RSUs @ $0.00 (acquired)
- 2025-11-13 — 2,454 RSUs @ $0.00 (acquired)
Total reported in this amendment: 28,012 RSUs (post 1-for-10 reverse split adjustment).
Shares owned after transaction: Not specified in the amended Form 4.
Vesting / other footnotes:
- F2: RSUs were granted as director compensation under the 2023 Equity Incentive Plan and vest in equal quarterly installments over three years, subject to continued service.
- F1: This filing is an amendment moving previously reported RSU information into Table I (correcting earlier Form 4s filed between June 18, 2024 and July 7, 2025).
- F3: Reported amounts reflect a 1-for-10 reverse stock split effected July 1, 2025.
Filing timeliness: This is an amended Form 4 filed April 1, 2026 to correct prior reports; the amendment indicates prior reporting changes but does not itself explain any penalties or compliance status.

Context

RSU grants are compensation awards, not open‑market purchases or sales; they only convert into shares as they vest, so they do not directly indicate an immediate buy/sell decision by the insider.
The $0.00 grant price is standard for RSUs (no cash paid at grant); any future taxable event will generally occur as units vest and are settled into shares.

Form 4/AAmended

Period: 2024-06-14

Director

Transactions

Holdings

Footnotes (3)

[F1]From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.
[F2]The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.
[F3]Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Signature

/s/ Francis Knuettel II, by power of attorney|2026-04-01

2 files